GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harpoon Therapeutics Inc (NAS:HARP) » Definitions » 10-Year RORE %

Harpoon Therapeutics (Harpoon Therapeutics) 10-Year RORE % : 0.00% (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Harpoon Therapeutics 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Harpoon Therapeutics does not have enough data to calculate 10-Year RORE %.


Harpoon Therapeutics 10-Year RORE % Historical Data

The historical data trend for Harpoon Therapeutics's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harpoon Therapeutics 10-Year RORE % Chart

Harpoon Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
10-Year RORE %
Get a 7-Day Free Trial - - - - -

Harpoon Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Harpoon Therapeutics's 10-Year RORE %

For the Biotechnology subindustry, Harpoon Therapeutics's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harpoon Therapeutics's 10-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harpoon Therapeutics's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Harpoon Therapeutics's 10-Year RORE % falls into.



Harpoon Therapeutics 10-Year RORE % Calculation

Harpoon Therapeutics's 10-Year RORE % for the quarter that ended in Sep. 2023 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2023 and 10-year before.


Harpoon Therapeutics  (NAS:HARP) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Harpoon Therapeutics 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Harpoon Therapeutics's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Harpoon Therapeutics (Harpoon Therapeutics) Business Description

Traded in Other Exchanges
Address
131 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.
Executives
Vijay K Lathi 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 2500 SAND HILL ROAD, SUITE 203, MENLO PARK CA 94025
Luke Nathaniel Walker officer: Chief Medical Officer C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Frank J Lanza officer: Principal Fin. & Acctng Ofc. C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lauren P Silvernail director 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Georgia Erbez officer: Chief Financial Officer 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Oncology Impact Fund (cayman) Management L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Alan Colowick director C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
New Leaf Bpo Associates Ii, L.p. 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
Ronald Hunt director, 10 percent owner C/O CREDIT SUISSE 1ST BOSTON PRV EQY, 11 MADISON AVENUE, NEW YORK NY 10010
New Leaf Bpo Management Ii, L.l.c 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
New Leaf Ventures Iii, L.p. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Associates Iii, L.p. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Management Iii, L.l.c. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Biopharma Opportunities Ii, L.p. 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170

Harpoon Therapeutics (Harpoon Therapeutics) Headlines

From GuruFocus